Pharma Equity Group A/S (CPH: PEG)

Pharma Equity Group Income Statement

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	15	11.81	5.78
Research & Development	9.76	9.08	5.5
Operating Expenses	29.16	25.29	11.28
Operating Income	-29.16	-25.29	-11.28
Interest Expense	-3.7	-1.56	-0.02
Interest & Investment Income	-	0.01	-
Pretax Income	-32.86	-26.84	-11.3
Income Tax Expense	-2.05	-2.23	-1.86
Net Income	-30.81	-24.61	-9.44
Net Income to Common	-30.81	-24.61	-9.44
Shares Outstanding (Basic)	1,093	1,080	954
Shares Outstanding (Diluted)	1,093	1,089	977
Shares Change (YoY)	12.08%	11.38%	-
EPS (Basic)	-0.03	-0.02	-0.01
EPS (Diluted)	-0.03	-0.02	-0.01
Free Cash Flow	-18.55	-16.7	-8.3
Free Cash Flow Per Share	-0.02	-0.02	-0.01
EBITDA	-28.92	-25.01	-11.02
D&A For EBITDA	0.25	0.28	0.26
EBIT	-29.16	-25.29	-11.28

Source: S&P Capital IQ. Standard template. Financial Sources.